Ginkgo Bioworks Holdings Inc.
DNA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DNA
Ginkgo Bioworks Holdings Inc. is a synthetic biology platform company that designs and engineers custom cells for customers across multiple industries, generating revenue through program fees and downstream value share.
Key risk: Cash burn and runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Ginkgo Bioworks Holdings Inc. is a synthetic biology platform company that designs and engineers custom cells for customers across multiple industries, generating revenue through program fees and downstream value share.
- Cash & equivalents of $172.0M as of 2026-06-30 [sec].
- Total revenue of $20.2M for the quarter ended 2026-06-30 [sec].
- Net loss of $46.7M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $716.1M as of 2026-06-30 [sec].
- Company anticipates expenditures will exceed revenue through at least the next 12 months from the date of its most recent filings [sec_mda · as of 2026-02-26].
What works
- Ginkgo's platform enables cell engineering across diverse end markets, potentially reducing customer R&D costs and timelines [sec · filed 2025-09-04].
- The company has raised substantial capital historically, including ~$1.5 billion from its SPAC merger and additional at-the-market offerings [sec_mda · as of 2025-02-25].
- Management believes existing cash and marketable securities are sufficient to fund operations for at least 12 months from the filing date of recent reports [sec_mda · as of 2025-08-07].
What to weigh
- Ginkgo has reported recurring net losses, with a net loss of $46.7M in the most recent quarter [sec].
- Cash reserves have declined significantly from $561.6M (Dec 2024) to $172.0M (Jun 2026) [sec_mda · as of 2025-02-25] [sec].
- The company acknowledges that expenditures will continue to exceed revenue for at least the next 12 months, requiring ongoing capital access [sec_mda · as of 2026-02-26].
- Forward-looking statements highlight risks including the need to raise additional capital and the dilutive effect of securities offerings [sec · filed 2025-09-04].
From the filings
Quoted directly from source documents.
Company expects expenditures to exceed revenue for at least 12 months
“We anticipate that our expenditures will exceed our revenue through at least the next 12 months from the date of filing of this Annual Report on Form 10-K”
SEC MD&A · February 26, 2026
Risks & what to watch (4)›
Key risks
- Cash burn and runway — Cash declined from $561.6M (Dec 2024) to $172.0M (Jun 2026); expenditures exceed revenue [sec] [sec_mda]
- Need for additional capital — Company may need to raise capital, which could be dilutive or unavailable [sec · filed 2025-09-04]
- Dependence on customer success — Revenue depends on customers' product development and commercialization [sec · filed 2024-05-13]
- Regulatory and market risks — Biotech sector faces regulatory changes and market conditions beyond company control [sec · filed 2025-09-04]
What to watch
- Cash runway updates in upcoming quarterly filings, especially given the decline to $172M [sec].
- Revenue growth trajectory and ability to narrow net losses [sec].
- Progress in customer programs and any downstream value share milestones [sec · filed 2025-09-04].
- Any new capital raises or strategic partnerships that could extend liquidity [sec · filed 2025-09-04].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Ginkgo Bioworks Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ginkgo Bioworks Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
15.7 months
D/E 1.36
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 13 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
172
Total value held
$184.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,828,856 | $23.5M |
| blackrock, inc. | 3,642,347 | $22.3M |
| viking global investors lp | 3,577,128 | $21.9M |
| anchorage capital group, l.l.c. | 1,746,363 | $10.7M |
| legal & general group plc | 1,661,587 | $10.2M |
| state street corp | 1,346,659 | $8.3M |
| forbes j m & co llp | 1,028,391 | $6.3M |
| geode capital management, llc | 1,009,362 | $6.2M |
| goldman sachs group inc | 929,862 | $5.7M |
| allianz asset management gmbh | 700,516 | $4.3M |
Showing top 10 of 172 institutional holders of Ginkgo Bioworks Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 10.1%
- Days to cover
- 4.7
- Shares short
- 5,233,195
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DNA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ginkgo Bioworks Holdings Inc.?
Ginkgo Bioworks Holdings Inc. is a synthetic biology platform company that designs and engineers custom cells for customers across multiple industries, generating revenue through program fees and downstream value share.
Who is the CEO of Ginkgo Bioworks Holdings Inc.?
Dr. Jason Kelly Ph.D. is the chief executive officer of Ginkgo Bioworks Holdings Inc. (DNA).
Where is Ginkgo Bioworks Holdings Inc. headquartered?
Ginkgo Bioworks Holdings Inc. (DNA) is headquartered in Boston, MA, United States.
What therapeutic areas does Ginkgo Bioworks Holdings Inc. focus on?
Ginkgo Bioworks Holdings Inc. develops therapies across Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.